Investigating the Effect of Vortioxetine in Adult ADHD Patients



Status:Completed
Conditions:Neurology, Psychiatric
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:18 - 55
Updated:4/17/2018
Start Date:December 2014
End Date:September 2016

Use our guide to learn which trials are right for you!

Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult
patients with ADHD in a 12 weeks study.

The study employed the Sequential Parallel Comparison Design (SPCD), a clinical study design
which intend to increase signal detection by using two stages of treatment:

- Stage 1 - first 6 weeks of the 12-weeks treatment period (Visit 2/Baseline 1 to Visit
5/Week 6)

- Stage 2 - last 6 weeks of the 12-weeks treatment period (Visit 5/Baseline 2 to Visit
8/Week 12)

In Stage 1, patients were randomized to placebo or vortioxetine 10 or 20mg. Patients on
vortioxetine 10 or 20mg/day during Stage 1 remained on the same treatment in Stage 2.
Responders to placebo in Stage 1 remained on Placebo in Stage 2. Patients who were placebo
non-responders during Stage 1, defined as patients with a <30% reduction in AISRS total score
from Baseline 1, were re-randomized to placebo or vortioxetine 10 or 20mg/day in Stage 2.

Inclusion Criteria:

- The patient is willing and able to attend study appointments within the specified time
windows.

- The patient is an outpatient.

- The patient is diagnosed with a primary diagnosis of ADHD according to the DSM-5™
classification.

- The patient has an AISRS total score ≥24.

- The patient has a CGI-S rating ≥4 (moderately ill or worse).

Exclusion Criteria:

- The patient has previously been treated with vortioxetine.

- The patient has any current psychiatric disorder (DSM-IV-TR™ criteria), other than
ADHD, as assessed using the Mini International Neuropsychiatric Interview (MINI).

- The patient has a known first-degree relative with bipolar disorder.

- The patient suffers from intellectual disability as evaluated by the Wechsler
Abbreviated Scale of Intelligence (WASI) II vocabulary and matrix.

- The patient suffers from organic mental disorders, or mental disorders due to a
general medical condition (DSM-5™ criteria).

- The patient has reported current use of, or has tested positive for, drugs of abuse
(opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates,
benzodiazepines, and cannabinoids). If a patient tests positive for opiates due to
incidental use of codeine containing medication, as assessed in a clinical interview,
the drug screen may be repeated up to three weeks later but the retest result must be
available from the central laboratory latest at Visit 2 and has to be negative for
this patient to be eligible for enrolment. If a patient tests positive for
amphetamines due to his/her ADHD current treatment, as confirmed by a clinical
interview, the patient is eligible for enrolment provided this treatment is
discontinued two weeks prior to the Baseline Visit.

- The patient has a history of two prior failed (<50% improvement in symptoms) adequate
trials of ADHD treatment.

- The patient has any other disorder for which the treatment takes priority over
treatment of ADHD or is likely to interfere with study treatment or impair treatment
compliance.

- The patient has a history of moderate or severe head trauma or other neurological
disorders or systemic medical diseases that are, in the investigator's opinion, likely
to affect central nervous system functioning.

- The patient has attempted suicide within the last 6 months or is at significant risk
of suicide (either in the opinion of the Investigator or defined as a "yes" to
suicidal ideation questions 4 or 5 or answering "yes" to suicidal behaviour on the
Columbia-Suicide Rating Scale (C-SSRS) within the last 12 months).

Other protocol defined inclusion and exclusion criteria do apply
We found this trial at
15
sites
Beverly Hills, California
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Alpharetta, Georgia
?
mi
from
Alpharetta, GA
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baltimore, Maryland
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bellevue, Washington
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Boston, Massachusetts
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bradenton, Florida
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Gainesville, Florida 32607
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Garden Grove, California
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Herndon, Virginia 20170
?
mi
from
Herndon, VA
Click here to add this to my saved trials
Las Vegas, Nevada
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Libertyville, Illinois
?
mi
from
Libertyville, IL
Click here to add this to my saved trials
National City, California
?
mi
from
National City, CA
Click here to add this to my saved trials
New York, New York
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials